The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...
Ibtrozi (taletrectinib) is approved for ROS1-positive NSCLC, showing high efficacy in TRUST-I and TRUST-II trials. Treatment-naive patients had response rates of 90% and 85%, with significant duration ...
Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). This is an ASCO ...
Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently ...
The US Food and Drug Administration (FDA) has fast-tracked a promising new gene therapy, KB707, which is inhaled as a fine mist for the targeted treatment of advanced or metastatic non-small-cell lung ...
What Is Hyrnuo, and Why Does It Matter? Hyrnuo (sevabertinib) is a new oral medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change known as ...
For patients with locally advanced non–small cell lung cancer (NSCLC), multidisciplinary team input optimizes outcomes by tailoring patient care, which is especially important during this era of ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results